In 2023, Jean-Jacques Bienaimé earned $23.10M in total compensation at BioMarin Pharmaceuticals, including $1.39M salary, $1.67M bonus and $19.53M in stock. Most recently sold 40,000 shares in May 2024. Currently holds stock worth $40.90M. Has donated $17.57M in stock to charitable causes. Led BioMarin Pharmaceuticals as CEO for 18 years.
Compensation History
Annual executive compensation data for Jean-Jacques Bienaimé, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$23.10M
Salary
$1.39M
Bonus
$1.67M
Other
$508.00K
Salary
$1.39MBoard Justification
The compensation philosophy is designed to attract and retain executive talent while aligning their interests with those of stockholders through performance-based incentives.
Bonus
$1.67MBoard Justification
Mr. Bienaimé’s annual cash incentive for 2023 as if he had remained employed as CEO in recognition of Mr. Bienaimé’s 2023 contribution and in light of the fact that he served as CEO for most of the year.
Other Compensation
$508.00KBoard Justification
This includes various forms of compensation such as health benefits, security measures, and consulting fees following his retirement.
Restricted Stock
Board Justification
The stock that vested in 2023 includes service-based RSUs and performance-based RSUs granted in prior years that were earned based on performance metrics over the applicable periods.
Performance Metrics
The performance metrics for the annual cash incentive included Managed Sales Revenue and Non-GAAP Income targets.
Jean-Jacques Bienaimé
Ex-CEO of BioMarin Pharmaceuticals
Education
Not specified
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
January 1, 1954 - 71 years ago
CEO of BioMarin Pharmaceuticals for
18 years 6 months (May 2005 - Nov 2023)
Previous Experience
Chairman, President and Chief Executive Officer of Genencor International, Inc.; Chairman, President and Chief Executive Officer of Sangstat Medical Corporation; Senior Vice President of Worldwide Marketing and Business Development at Rhône-Poulenc Rorer Pharmaceuticals; various roles at Genentech, Inc.
Other BioMarin Pharmaceuticals CEOs
Holdings
Track Jean-Jacques Bienaimé's stock holdings and portfolio value over time.
Total Stock Sold
$234.95M
$234.95M
2,853,657 BMRN shares
What if they kept their stock?
If Jean-Jacques Bienaimé didn't sell their stock, today they would have:
Extra BMRN2,853,657 shares worth $152.13M.
This is -35.25% and $82.82M less than what they got when they sold the stock.
Charitable Transactions
329,607 shares
BMRN
Recent Charitable Transactions
5,600 shares
BMRN
Dec 31, 2023
Charity
200 shares
BMRN
Feb 7, 2023
Charity
100 shares
BMRN
Dec 31, 2022
Charity
700 shares
BMRN
Dec 10, 2021
Charity
425 shares
BMRN
Jul 9, 2020
Charity
630 shares
BMRN
Dec 3, 2019
Charity
Insider Trading
Jean-Jacques Bienaimé's recent stock transactions, purchases, and sales filed with the SEC.
$3.26M
BMRN at $81.38/share
May 9, 2024
Sale
$3.65M
BMRN at $91.13/share
Apr 11, 2024
Sale
$172.22K
BMRN at $86.11/share
Mar 5, 2024
Sale
$90.35K
BMRN at $90.35/share
Feb 27, 2024
Sale
143,601 shares
BMRN
Feb 27, 2024
Received
$2.67M
BMRN at $89.03/share
Jan 18, 2024
Sale
$3.70K
BMRN at $92.60/share
Jan 18, 2024
Small Acquisition
$1.95M
BMRN at $97.29/share
Jan 8, 2024
Sale
$4.95K
BMRN at $99.05/share
Jan 8, 2024
Small Acquisition
Rivals
Compare Jean-Jacques Bienaimé with competitor CEOs and industry peers.